Curateq Biologics Private Limited, a wholly owned subsidiary of the Company receives CDSCO Marketing Autorisation (Form CT 23) for Bevqolva (Bevacizumab Biosimilar).
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has received marketing authorisation from CDSCO for Bevqolva, a bevacizumab biosimilar. The drug is indicated for metastatic carcinoma of the colon or rectum. Manufacturing is permitted at CuraTeQ's Hyderabad facility. The product will be available in two vial presentations: 100 mg/4mL and 400 mg/16mL. This marks Aurobindo's entry into the biosimilar space for oncology treatment.
This regulatory approval represents a positive step for Aurobindo Pharma as it diversifies into biologics and biosimilars, potentially opening a new revenue stream once the product is commercialised in the Indian market.